| Editor's Choice: Heart Health | There is an increased risk that these devices will not provide audible alerts for low or high blood glucose levels. The FDA has ruled that this is a Class I recall, highlighting the safety risks associated with missed alerts. There is an increased risk that these devices will not provide audible alerts for low or high blood glucose levels. The FDA has ruled that this is a Class I recall, highlighting the safety risks associated with missed alerts. | | |
| Former ACC president Kim Allan Williams Sr., MD, thinks cardiologists should be much more proactive. Encouraging healthy eating habits now, for example, can keep patients out of the hospital later in life and reduce healthcare spending. Former ACC president Kim Allan Williams Sr., MD, thinks cardiologists should be much more proactive. Encouraging healthy eating habits now, for example, can keep patients out of the hospital later in life and reduce healthcare spending. | | |
| Use of the drug more than doubles a person's risk of dying from heart disease, according to a new analysis of 24 different studies. In a separate editorial, two physicians shared their concerns and highlighted the importance of discussing these risks with patients. Use of the drug more than doubles a person's risk of dying from heart disease, according to a new analysis of 24 different studies. In a separate editorial, two physicians shared their concerns and highlighted the importance of discussing these risks with patients. | | |
| The group highlighted the proven effectiveness of these drugs, especially semaglutide and tirzepatide, while noting that eligibility, affordability and availability will still play key roles in any treatment decisions. The group highlighted the proven effectiveness of these drugs, especially semaglutide and tirzepatide, while noting that eligibility, affordability and availability will still play key roles in any treatment decisions. | | |
| The cuffless technology, which has already gained CE mark approval, should make its U.S. debut in 2026. The cuffless technology, which has already gained CE mark approval, should make its U.S. debut in 2026. | | |
| The new warnings, first proposed to Pfizer and Moderna in April, are now officially required by the FDA. They provide additional information about the potential risks of myocarditis and/or pericarditis associated with these vaccines. The new warnings, first proposed to Pfizer and Moderna in April, are now officially required by the FDA. They provide additional information about the potential risks of myocarditis and/or pericarditis associated with these vaccines. | | |
| The ongoing debate continues. The team behind this latest analysis pointed to more than 40 years of research to make its point. The ongoing debate continues. The team behind this latest analysis pointed to more than 40 years of research to make its point. | | |
| Janet Wei, MD, examined the key differences between men and women when it comes to cardiovascular disease. These differences, she said, highlight why female patients need their very own treatment guidelines. Janet Wei, MD, examined the key differences between men and women when it comes to cardiovascular disease. These differences, she said, highlight why female patients need their very own treatment guidelines. | | |
| Researchers explored more than 52 years of data, highlighting several key trends in the Journal of the American Heart Association. Researchers explored more than 52 years of data, highlighting several key trends in the Journal of the American Heart Association. | | |
| Semaglutide, tirzepatide and other GLP-1 drugs appear to provide significant value for patients with moderate PAD. Semaglutide, tirzepatide and other GLP-1 drugs appear to provide significant value for patients with moderate PAD. | | |
| |
|
| ![]() | |
|